OmniAb (OABI) Cash & Current Investments (2021 - 2026)
OmniAb (OABI) reported Cash & Current Investments of $43.0 million for Q1 2026, down 1.44% year-over-year from $43.6 million in Q1 2025, and down 11.56% quarter-over-quarter from $48.6 million in Q4 2025.
OmniAb (OABI) Cash & Current Investments (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Cash & Current Investments data on file, last reported at $43.0 million in Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $43.0 million, down 1.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.0 million (down 1.44% YoY), and the FY2025 annual result was $48.6 million, down 1.76% from the prior year.
- Cash & Current Investments fell to $43.0 million in Q1 2026 per OABI's latest filing, from $48.6 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $113.6 million in Q1 2023 and troughed at $19847.0 in Q3 2022.
- A 5-year average of $56.5 million and a median of $57.2 million in 2024 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments plunged 94.52% in 2022, then surged 486764.51% in 2023.
- A 5-year view of Cash & Current Investments shows it stood at $88.3 million in 2022, then slipped by 1.45% to $87.0 million in 2023, then tumbled by 43.15% to $49.5 million in 2024, then fell by 1.76% to $48.6 million in 2025, then fell by 11.56% to $43.0 million in 2026.
- Business Quant data shows OABI's Cash & Current Investments at $43.0 million in Q1 2026, $48.6 million in Q4 2025, and $59.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 42.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.97 Mn |
| Dec 31, 2025 | 48.58 Mn |
| Sep 30, 2025 | 59.50 Mn |
| Jun 30, 2025 | 41.62 Mn |
| Mar 31, 2025 | 43.60 Mn |
| Dec 31, 2024 | 49.45 Mn |
| Sep 30, 2024 | 59.38 Mn |
| Jun 30, 2024 | 57.23 Mn |
| Mar 31, 2024 | 69.01 Mn |
| Dec 31, 2023 | 86.98 Mn |
| Sep 30, 2023 | 96.63 Mn |
| Jun 30, 2023 | 103.15 Mn |
| Mar 31, 2023 | 113.61 Mn |
| Dec 31, 2022 | 88.27 Mn |
| Sep 30, 2022 | 19,847.00 |
| Jun 30, 2022 | 159,194.00 |
| Mar 31, 2022 | 434,629.00 |
| Sep 30, 2021 | 362,203.00 |
| Jun 30, 2021 | 36,145.00 |